Idecabtagene vicleucel
Idecabtagene vicleucel is a type of CAR T-cell therapy that is composed of genetically modified T-cells from the patient, which are directed against the B-cell maturation antigen.
The drug is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received multiple lines of therapy.